Menstrual blood derived mesenchymal stem cell therapy - S-Evans

Drug Profile

Menstrual blood derived mesenchymal stem cell therapy - S-Evans

Alternative Names: C'elle menstrual stem cells; Human menstrual blood derived mesenchymal stem cell therapy - S-Evans; MenSC

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cryo-Cell International
  • Developer S-Evans Biosciences; Zhejiang University
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute lung injury; Liver cirrhosis; Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2017 No recent reports on development identified - Phase-I/II for Acute lung injury in China (IV)
  • 01 Sep 2017 No recent reports on development identified - Phase-I/II for Cirrhosis in China (IV)
  • 01 Sep 2017 No recent reports on development identified - Phase-I/II for Type-1 diabetes mellitus in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top